The use of computer-assisted video image analysis for the quantification of CD8(+) T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens

被引:92
作者
Herr, W
Linn, B
Leister, N
Wandel, E
zumBuschenfelde, KHM
Wolfel, T
机构
[1] UNIV MAINZ,MED KLIN & POLIKLIN 1,D-55101 MAINZ,GERMANY
[2] LEICA GMBH,D-64625 BENSHEIM,GERMANY
关键词
CD8(+) T lymphocytes; peptides; CMV; influenza; ELISPOT assay; TNF-alpha; image analysis;
D O I
10.1016/S0022-1759(97)00019-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Enzyme-linked immunospot (ELISPOT) analysis is a sensitive technique for the detection and quantification of single T lymphocytes forming cytokine spots after antigen contact in vitro. Herein computer-assisted video image analysis (CVIA) was applied to automatically determine the number and size of tumor necrosis factor alpha (TNF-alpha) spots formed by single blood-derived CD8(+) T cells after contact with peptide-loaded target cells. With CVIA and TNF-alpha ELISPOT analysis we quantified CD8(+) T cells responsive to HLA-A2.1-binding tyrosinase and influenza matrix peptides in healthy donors. We followed the course of the virus-specific T cell response in two HLA-A2-positive patients with reactivation of latent cytomegalovirus (CMV) infection during immunosuppressive therapy. The test proved sufficiently sensitive to detect in the blood of both patients a temporary expansion of CD8(+) T lymphocytes reactive with a known immunogenic HLA-A2.1-binding peptide from glycoprotein B of CMV. Reactivity to peptide antigens was not only reflected by numeric increases of spot formation, but also by the appearance of larger spot areas, presumably formed by strongly peptide-reactive CD8(+) T cells. We conclude that the combined use of the TNF-alpha ELISPOT assay and CVIA allows reliable monitoring of the T cell responsiveness to peptide antigens in peripheral blood.
引用
收藏
页码:141 / 152
页数:12
相关论文
共 39 条
[1]  
BEDNAREK MA, 1991, J IMMUNOL, V147, P4047
[2]  
BESSIS M, 1973, LIVING BLOOD CELLS T, P419
[3]   FROM DEFINED HUMAN TUMOR-ANTIGENS TO EFFECTIVE IMMUNIZATION [J].
BOON, T ;
GAJEWSKI, TF ;
COULIE, PG .
IMMUNOLOGY TODAY, 1995, 16 (07) :334-336
[4]   HUMAN CYTOMEGALOVIRUS-SPECIFIC CYTO-TOXIC T-CELLS - RELATIVE FREQUENCY OF STAGE-SPECIFIC CTL RECOGNIZING THE 72-KD IMMEDIATE EARLY PROTEIN AND GLYCOPROTEIN-B EXPRESSED BY RECOMBINANT VACCINIA VIRUSES [J].
BORYSIEWICZ, LK ;
HICKLING, JK ;
GRAHAM, S ;
SINCLAIR, J ;
CRANAGE, MP ;
SMITH, GL ;
SISSONS, JGP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (03) :919-931
[5]   A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [J].
Borysiewicz, LK ;
Fiander, A ;
Nimako, M ;
Man, S ;
Wilkinson, GWG ;
Westmoreland, D ;
Evans, AS ;
Adams, M ;
Stacey, SN ;
Boursnell, MEG ;
Rutherford, E ;
Hickling, JK ;
Inglis, SC .
LANCET, 1996, 347 (9014) :1523-1527
[6]   THE TYROSINASE GENE CODES FOR AN ANTIGEN RECOGNIZED BY AUTOLOGOUS CYTOLYTIC T-LYMPHOCYTES ON HLA-A2 MELANOMAS [J].
BRICHARD, V ;
VANPEL, A ;
WOLFEL, T ;
WOLFEL, C ;
DEPLAEN, E ;
LETHE, B ;
COULIE, P ;
BOON, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :489-495
[7]   QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE [J].
CARMICHAEL, A ;
JIN, X ;
SISSONS, P ;
BORYSIEWICZ, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :249-256
[8]   PRESENTATION OF VIRAL-ANTIGEN CONTROLLED BY A GENE IN THE MAJOR HISTOCOMPATIBILITY COMPLEX [J].
CERUNDOLO, V ;
ALEXANDER, J ;
ANDERSON, K ;
LAMB, C ;
CRESSWELL, P ;
MCMICHAEL, A ;
GOTCH, F ;
TOWNSEND, A .
NATURE, 1990, 345 (6274) :449-452
[9]   VACCINES GET A NEW TWIST [J].
COHEN, J .
SCIENCE, 1994, 264 (5158) :503-505
[10]   PRECURSOR FREQUENCY-ANALYSIS OF HUMAN CYTOLYTIC T LYMPHOCYTES DIRECTED AGAINST AUTOLOGOUS MELANOMA-CELLS [J].
COULIE, PG ;
SOMVILLE, M ;
LEHMANN, F ;
HAINAUT, P ;
BRASSEUR, F ;
DEVOS, R ;
BOON, T .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (02) :289-297